Evidence map›Paper›PMID 41394693›Full record

ArticlebioRxiv : the preprint server for biology2025

Antibody-Protein L Functionalized Microparticles for Detection of Surface Markers in Heterogeneous Colorectal Lesions.

Saleh Ramezani, Niki M Zacharias, William Norton, Jennifer S Davis, Abishai Dominic, Ryan Armijo, Muxin Wang, Richard E Wendt, Daniel D Carson, Daniel A Harrington and 2 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Saleh RamezaniDepartment of Diagnostic and Biomedical Sciences, School of Dentistry, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Niki M ZachariasDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
William NortonDepartment of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jennifer S DavisDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abishai DominicDepartment of Diagnostic and Biomedical Sciences, School of Dentistry, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Ryan ArmijoDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Muxin WangDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Richard E WendtMD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences (GSBS), Houston, TX, USA.
Daniel D CarsonDepartment of BioSciences, Rice University, Houston, TX, USA.
Daniel A HarringtonDepartment of Diagnostic and Biomedical Sciences, School of Dentistry, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Mary C Farach-CarsonDepartment of Diagnostic and Biomedical Sciences, School of Dentistry, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Pratip K BhattacharyaDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

TRAINING PROGRAM IN COMPUTATIONAL BIOLOGY AND MEDICINET15LM007093 · NLM · RICE UNIVERSITY · PI Lydia E. Kavraki · 1992 to 2026
$20.8M
Targeted Hyperpolarized Molecular Beacons for Colorectal Cancer DetectionR21EB031217 · NIBIB · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BHATTACHARYA, PRATIP K. · 2021 to 2023
$648k
NIBIB NIH HHS R21 EB031217NLM NIH HHS T15 LM007093
6 · The paper itself

Abstract

Visualization of colorectal cancer (CRC) lesions is complicated by their location in the colon and tumor morphology. Reliance on a single surface biomarker for direct identification risks false negatives due to temporal changes and/or tumor heterogeneity. We developed a multiplexed system of complementary biomarker targets in an effort to capture a broader range of lesions with diverse temporal and/or phenotypic expression. We identified Mucin-1 (MUC1) and epithelial cell adhesion molecule (EPCAM) as useful targeting pairs by examining multiple colon tumor subtypes in a standard tissue array, and by surveying multiple CRC cell lines, both as 2D cultures and as 3D tumoroids, for the presence of the CRC surface biomarkers. We demonstrated the utility of a "universal" surface functionalization approach using Antibody-Protein L functionalized microparticles (APL-MPs) that enabled the simultaneous incorporation of antibodies recognizing MUC1 and EPCAM. Using CRC cell heterogeneous tumoroids expressing both MUC1 and EPCAM (HET-tumoroids) and orthotopic animal cancer models designed to express both surface antigens, we demonstrated that: 1) APL-MPs identified MUC1- and EPCAM-positive tumoroids in proportion to antigen expression; 2) APL-MPs detected CRC surface antigens on the luminal colon surface

Identifiers

PMID41394693
PMCPMC12697353

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.